A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
Status:
Completed
Trial end date:
2020-10-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability profile of TB-403
(humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects
with relapsed or refractory Medulloblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
Oncurious NV
Collaborators:
Beat Childhood Cancer BioInvent International AB Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC)